Baird lowered the firm’s price target on Regeneron (REGN) to $587 from $652 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results while noting Eylea missed already bad expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $700 from $750 at Wells Fargo
- Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
- Regeneron Buy Rating: Navigating Challenges with a Promising Pipeline and Strategic Investments
- Regeneron’s Eylea Challenges Prompt Underperform Rating Amid Market Erosion and FDA Setback
- Regeneron Reports Strong Q1 2025 Financial Results